E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052106 |
E.1.2 | Term | Rhinosinusitis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of a 15-days treatment with a herbal medicinal product (BNO 1016) for treatment of acute rhinosinusitis in adult patients compared to placebo on the basis of the major symptom score (MSS) assessed by the investigator
|
|
E.2.2 | Secondary objectives of the trial |
To assess the safety of BNO 1016 compared to placebo applied in patients with acute rhinosinusitis
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Signed informed consent and data protection declaration 2. Male and female outpatients aged ≥18 and ≤ 75 years 3. Diagnosis of acute rhinosinusitis - characterised by a major symptom score* (MSS) ≥ 8 and ≤12 points (range: mini-mum 0, maximum 15 points) - individual score for facial pain / pressure ≥ 1 (mild) and ≤ 2 (moderate) - confirmed by ultrasonography of paranasal sinuses - with presence of symptoms ≤ 3 days prior to inclusion
*Out of the 5 main rhinosinusitis symptoms at least 3 must be present. Among these the presence of nasal con-gestion and facial pain / pressure is mandatory.
|
|
E.4 | Principal exclusion criteria |
1. Chronic rhinosinusitis 2. Polyposis nasi 3. Cystic fibrosis 4. Anatomical deviations of the nasal septum that significantly impair nasal and paranasal ventilation / airflow 5. Acute symptoms of a known allergic rhinitis 6. Patients with asthma who have a history of exacerbations within 30 days prior to study inclusion 7. Known hypersensitivity to study medication or excipients 8. Underlying diseases leading to significant immune deficiency 9. Signs or symptoms of fulminant bacterial sinusitis (e.g. fever > 38.5 °C, orbital complications, severe unilateral frontal headache or toothache) 10. Odontogenic sinusitis 11. Treatment with systemic or nasal antibiotics or nasal or systemic corticosteroids (excluding inhaled corticosteroids for mild to moderate persistent asthma) within the last 4 weeks prior to study inclusion 12. Treatment with decongestant preparations, analgesics (including systemic NSAIDs, except Paracetamol), mucolytics / secretolytics, antihistamines, or alternative medicine preparations for treatment of common cold like symptoms or with immunomodulating properties within the last 7 days prior to study inclusion 13. Patients requiring antibiotic treatment for any condition at study entry 14. Pregnancy or lactation 15. Severe diseases of liver or kidney 16. Severe somatopathic, neurological and / or psychiatric diseases 17. Malignant growth (actual, condition after carcinoma not longer than 5 years without relapse) 18. History of alcohol or drug abuse 19. Parallel participation in another study, participation in a study within less than 6 weeks prior to study entry, or previous participation in this same study 20. Known to be, or suspected of being unable to comply with the study protocol (e.g. no permanent address, history of drug abuse, known to be non-compliant or presenting an unstable psychiatric history) 21. Legal incapacity and / or other circumstances rendering the patient unable to understand the nature, scope and possible impact of the study 22. Patients in custody by juridical or official order 23. Evidence of an uncooperative attitude 24. Patients who have difficulties in understanding the language (German) in which the patient information is given 25. Patients who are members of the staff of the study centre, staff of the sponsor or CRO, the investigator him- / herself or close relatives of the investigator
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is defined as the mean major symptom score (MSS) assessed at the end of treatment on Visit 5 (Day 14). The MSS is the sum of the investigator’s morning as-sessment of the 5 main rhinosinusitis symptoms on Visit 1 (Day 0), Visit 2 (Day 3), Visit 3 (Day 7), Visit 4 (Day 10) and Visit 5 (Day 14) based on the 4-point rating scale given below: [local language] 0 = none / not present [nicht vorhanden] 1 = mild [leicht] 2 = moderate [mäßig] 3 = severe [schwer] The 5 main rhinosinusitis symptoms are: [local language] - rhinorrhea (anterior discharge) [Nasenlaufen nach vorne] - postnasal drip [Nasenlaufen in den Rachen] - nasal congestion [Verstopfte Nase] - headache [Kopfschmerzen] - facial pain / pressure [Gesichtsschmerz oder -druck]
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 35 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of Trial will be end of April 2010 at last patient out (last patient last visit) of alltogether 380 patients |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |